Equities research analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce $59.43 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Crispr Therapeutics’ earnings, with estimates ranging from $14.30 million to $76.70 million. Crispr Therapeutics reported sales of $120,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 49,425%. The firm is scheduled to announce its next quarterly earnings results on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current financial year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts forecast that the business will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

Several equities research analysts have weighed in on the company. Canaccord Genuity increased their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a report on Monday, December 16th. Goldman Sachs Group lifted their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Finally, BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $71.38.

Shares of CRSP stock traded down $1.59 during trading hours on Thursday, reaching $59.32. 1,724,512 shares of the company’s stock were exchanged, compared to its average volume of 979,781. The stock’s 50 day moving average is $65.89 and its 200-day moving average is $51.06. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -17.24 and a beta of 3.31. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a fifty-two week low of $27.50 and a fifty-two week high of $74.00.

In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 in the last ninety days. 21.40% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Nikko Asset Management Americas Inc. increased its position in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares during the period. Wells Fargo & Company MN increased its holdings in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the period. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics in the 3rd quarter valued at $21,167,000. Finally, Morgan Stanley increased its holdings in Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after buying an additional 16,361 shares during the period. 49.82% of the stock is currently owned by institutional investors and hedge funds.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: What is a stock buyback?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link